摘要
目的:通过辛伐他汀对不稳定性心绞痛患者超敏C反应蛋白(HSCRP)的作用,探讨在急性冠脉综合征患者中应用他汀类药物的必要性。方法:共入选45例不稳定心绞痛患者,随机分为辛伐他汀组(观察组)和常规治疗组(对照组),两组均于入院后第二天及六周后抽血测定血脂(TC,TG,LDL-C,HDL-C)及C反应蛋白。结果:对照组六周后血脂及HS-CRP无明显变化(P>0.05),观察组六周后TC,TG及LDLC有下降(P<0.05),HDL-C有明显升高(P<0.01),HSCRP有明显下降(P<0.01)。结论:辛伐他汀除有很好的调脂作用外,还能有效地抑制急性冠脉综合征患者的炎症反应,早期应用可以抑制冠脉炎症反应。
Objective:To evaluate the effect of simvastastin to (HS-CRP) on C reaction protein in the patients with unstable Angina and explore the necessity of taking statins to the patients with acute coronary artery syndromes. Methods: Twenty-five patients were randomly selected to accept the simvastastin as the treatment group from forty-five persons with unstable angina. The serum lipid (TC, TG, CDC-C, HDC-C) and HS-CRP from those two groups were detected on the second day and after six weeks. Results: The serum lipid and HS-CRP in control group had not obvious changes(P>0.05)after six weeks of their being in hospital. While at the same time the TC, TG and LDL-C of the treatment group was declined(P<0.05). Their HDL-C was arisen evidently(P<0.01). The HS-CRP has declined clearly(P<0.01).Conclusion: Beside the effective influence of regulating the serum lipid, simvastastin could prohibit the inflammation reaction of the patients of the acute coronary artery syndromes effectively. Using it on earlier period could also prohibit the reaction of coronary artery inflammation.
出处
《实用临床医学(江西)》
CAS
2005年第6期9-10,共2页
Practical Clinical Medicine
关键词
辛伐他汀
C反应蛋白
冠状动脉疾病
simvastastin
C reaction protein
coronary artery disease